CRCM  Vol.2 No.1 , March 2013
Psoriatic skin lesions induced by tumor-necrosis-factor-alpha-therapy
Abstract: A 46-year-old, caucasian woman suffering from Crohn’s disease and a 35-year-old woman suffering from ankylosing spondylitis were treated with the TNFα blocker infliximab and developed psoriasiform skin lesions. The pathophysiology of this paradoxical clinical response as a newly recognized adverse effect of TNFα antagonists is unknown. According to the literature, this type of newly triggered psoriasis may occur any time after initiation of TNFα antagonist therapy and responds to classic antipsoriatic treatment. The phenomenon warrants attention, especially when considering anti-TNFα treatment in various skin diseases besides psoriasis.
Cite this paper: Faul, A. , Folwaczny, C. , Aigner, B. , Hein, R. , Ring, J. and Plötz, S. (2013) Psoriatic skin lesions induced by tumor-necrosis-factor-alpha-therapy. Case Reports in Clinical Medicine, 2, 85-88. doi: 10.4236/crcm.2013.21023.

[1]   Keating, G.M. and Perry, C.M. (2002) Infliximab: An updated review of its use in Crohn’s disease and rheumatoid arthritis. BioDrugs, 16, 111-148. doi:10.2165/00063030-200216020-00005

[2]   Braun, J. and Sieper, J. (2004) Biological therapies in the spondyloarthritides-the current state. Rheumatology (Oxford), 43, 1072-1084. doi:10.1093/rheumatology/keh205

[3]   Mease, P. (2004) TNFalpha therapy in psoriatic arthritis and psoriasis. Annals of the Rheumatic Diseases, 63, 755-758. doi:10.1136/ard.2004.020719

[4]   Stratigos, A.J., Antoniou, C., Stamathioudaki, S., et al. (2004) Discoid lupus erythematosus-like eruption induced by infliximab. Clinical and Experimental Dermatology, 29, 150-153. doi:10.1111/j.1365-2230.2004.01471.x

[5]   Lebas, D., Staumont-Salle, D., Solau-Gervais, E., et al. (2007) Cutaneous manifestations during treatment with TNF-alpha blockers: 11 cases. Annales de Dermatologie et de Venereologie, 134, 337-342. doi:10.1016/S0151-9638(07)89187-3

[6]   Flendrie, M., Vissers, W.H., Creemers, M.C., et al. (2005) Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: A prospective study. Arthritis Research & Therapy, 7, R666-R676. doi:10.1186/ar1724

[7]   Devos, S.A., Van Den Bossche, N., De Vos, M. and Naeyaert, J.M. (2003) Adverse skin reactions to anti-TNFalpha monoclonal antibody therapy. Dermatology, 206, 388-390. doi:10.1159/000069965

[8]   Starmans-Kool, M.J., Peeters, H.R. and Houben, H.H. (2005) Pustular skin lesions in patients treated with infliximab: Report of two cases. Rheumatology International, 25, 550-552. doi:10.1007/s00296-004-0567-5

[9]   Sfikakis, P.P., Iliopoulos, A., Elezoglou, A., et al. (2005) Psoriasis induced by anti-tumor necrosis factor therapy: A paradoxical adverse reaction. Arthritis & Rheumatism, 52, 2513-2518. doi:10.1002/art.21233

[10]   Takahashi, H., Hashimoto, Y., Ishida-Yamamoto, A., et al. (2007) Psoriasiform and pustular eruption induced by infliximab. The Journal of Dermatology, 34, 468-472. doi:10.1111/j.1346-8138.2007.00312.x

[11]   de Gannes, G.C., Ghoreishi, M., Pope, J., et al. (2007) Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Archives of Dermatology, 143, 223-231. doi:10.1001/archderm.143.2.223

[12]   Roux, C.H., Brocq, O., Leccia, N., et al. (2007) New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: A class effect? The Journal of Rheumatology, 34, 434-437.

[13]   Cohen, J.D., Bournerias, I., Buffard, V., et al. (2007) Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: A case series. The Journal of Rheumatology, 34, 380-385.

[14]   Pirard, D., Arco, D., Debrouckere, V. and Heenen, M. (2006) Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: Three further cases and current overview. Dermatology, 213, 182-186. doi:10.1159/000095033

[15]   Collamer, A.N., Guerrero, K.T., Henning, J.S. and Battafarano, D.F. (2008) Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action. Arthritis & Rheumatism, 59, 996-1001. doi:10.1002/art.23835

[16]   Palucka, A.K., Blanck, J.P., Bennett, L., et al. (2005) Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proceedings of the National Academy of Sciences of the United States of America, 102, 3372-3377. doi:10.1073/pnas.0408506102

[17]   Aeberli, D., Seitz, M., Juni, P. and Villiger, P.M. (2005) Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors. Rheumatology (Oxford), 44, 172-175. doi:10.1093/rheumatology/keh437

[18]   Nestle, F.O., Conrad, C., Tun-Kyi, A., et al. (2005) Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. The Journal of Experimental Medicine, 202, 135-143. doi:10.1084/jem.20050500

[19]   Funk, J., Langeland, T., Schrumpf, E. and Hanssen, L.E. (1991) Psoriasis induced by interferon-alpha. British Journal of Dermatology, 125, 463-465. doi:10.1111/j.1365-2133.1991.tb14774.x

[20]   van der Fits, L., van der Wel, L.I., Laman, J.D., et al. (2004) In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. Journal of Investigative Dermatology, 122, 51-60. doi:10.1046/j.0022-202X.2003.22113.x

[21]   Gilliet, M., Conrad, C. and Geiges, M., et al. (2004) Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Archives of Dermatology, 140, 1490-1495. doi:10.1001/archderm.140.12.1490